1 |
Chiou CF, Hay JW, Wallace JF, Bloom BS, Neumann PJ, Sullivan SD, Yu HT, Keeler EB, Henning JM, Ofman JJ. Development and Validation of a Grading System for the Quality of Cost-effectiveness Studies. Medical Care 2003; 41(1):32-44
DOI
ScienceOn
|
2 |
Drummond M and McGuire A. Economic Evaluation in Health Care: Merging theory with practice. Oxford University Press; 2001. pp. 256-276
|
3 |
Drummond MF and Jefferson TO. Guidelines for Authors and Peer Reviewers of Economic Submissions to the BMJ. BMJ 1911; 313:275-283
|
4 |
Drummond MF, O'Brien B, Stoddart GL, and Torrance GW. Methods for the Economic Evaluation of Health Care Programmes, Ed. Oxford Medical Publications; 1997. pp. 39-41
|
5 |
National Institute for Clinical Excellence. Guide to the Method of Technology Appraisal. April 2004. Available from URL: http://www.nice.org.uk/page.aspx?o=201971
|
6 |
Ofman JJ, Sullivan SD, Neuman PJ, Choiu CF, Hennig JM, Wade SW, Hay JW. Examining the Value and Quality of Health Economic Analysis: Implications of Utilizing the QHES, JMCP. 2003;9(1): 53-61
|
7 |
최용준, 이태진, 이의경, 김윤. 우리나라 의약품 비용효과분석 연구의 현황. 보건경제연구 2003; 9(1): 59-78
|
8 |
Tarn TYH, Smith MD, Pharmacoeconomic Guidelines Around the World, ISPOR newsletter CONNECTIONS 2004; 10(4)
|
9 |
이건세, Brouwer WBF, 이상일, 구혜원. 보건의료 경제성평가 방법론 고찰-연구설계와 비용추정을 중심으로. 보건행정학회지 2004; 14(2):58-77
|
10 |
이의경, 배은영, 이태진, 최용준, 박은자, 김동숙. 보험의약품의 급여관리제도 개선방안. 한국보건사회연구원.보건복지부 2003
|
11 |
Baladi JF, MenonD, Otten N. Use of Economic Evaluation Guidelines: 2 years' Experience in Canada. Health Econonomics. 1998; 7:221-227
DOI
ScienceOn
|
12 |
Briggs A and Fenn P. Trying to do Better than Average: A coomentary on 'Statstical Inference for CostEffectiveness Ratios'. Health Economics 1997; 6:491-495
DOI
ScienceOn
|
13 |
Canadian Coordinating Office for Health Technology Assessment, Guidelines for Authors of CCOHTA Health Technology Assessment Reports, June 2001 Revised May 2003. Available from URL: https://www.ccohta.ca/entry_e.html
|
14 |
George B, Harris A, Mitchell A Costeffectiveness Analysis and the Consistency of Decision Making: Evidence from Pharmaceutical Reimbursement in Australia (1991 to 1996). Pharmacoeconomics. 2001; 19(11):1103-9
DOI
ScienceOn
|
15 |
Drummond MF. A Reappraisal of Economic Evaluation of Pharmaceuticals: Science or Marketing? Pharmacoeconomics 1998 Jul; 14(1); 1-9
|
16 |
Drummond MF. The Use of Health Economic Information by Reimbursement Authorities. Rheumatology (Oxford). 2003 Nov;42 Suppl 3:iii60-3
DOI
ScienceOn
|
17 |
Enstrom A, Jacob J, Lundin D, Odeberg S, Ramsberg J. Examinging the Quality of Health Economic Analyses Submitted to the Pharmaceutical Benefits Board in Sweden. ISPOR Annual Meeting Poster Presentation. 2005
|
18 |
Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in Health and Medicine. Oxford University Press 1996
|
19 |
Helmgren J. Berggren F, Anderson F. Health Economic Guidelines -Similarities, Differences and Some Implications. Value in Health 2001; 4(3); 224-250
|
20 |
Hill SR, Mitchell AS, Herny DA. Problems With the Interpretation of Pharmacoeconomic Analyses: A Review of Submissions to the Australian Pharmaceutical Benefits Scheme. JAMA. 2000 April; 283(16); 2116-2121
DOI
ScienceOn
|
21 |
Welte R, Feenstra T, Jager H and Leid R, A Decision Chart for Assessing and Improving the Transferability of Economic Evaluation Results Between Countries, Pharmacoeconomics 2004; 22(13): 857-876
DOI
ScienceOn
|
22 |
Anis AH and Gagnon Y. Using Economic Evaluations to Make Formulary Coverage Decisions. So much for Guidelines. Pharmacoeconomics. 2000 Jul; 18(1): 55-62
DOI
ScienceOn
|
23 |
http:;/www.ispor.org/PEguidelines/index.asp
|
24 |
Sculpher M, Fenwick E, Claxton K, Assessing Quality in Decision Analytic Cost-Effectiveness Models. Pharmacoeconomics 2000 May; 17(5); 461-477
DOI
ScienceOn
|